Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation | Financial Post

Spectral Medical extends its exclusive supply and distribution agreement with Baxter Healthcare for 10 years post U.S. FDA approval of PMX, a therapeutic device for septic shock. Baxter's commitment supports Spectral's commercialization strategy, with plans to transfer rights to a new Kidney Care company upon separation. Spectral's Tigris Trial progresses, aiming to enhance treatment for endotoxic septic shock.